Literature DB >> 24041031

Relationship between oxidant and antioxidant activity in hyperemesis gravidarum.

Yüksel Onaran1, Hasan Kafali, Candan İltemir Duvan, Esra Keskin, Hakim Celik, Ozcan Erel.   

Abstract

OBJECTIVE: To evaluate oxidant and antioxidant activity in patients with hyperemesis gravidarum (HG) by using serum total antioxidant activity (TAO), total free sulfhydryl (-SH), ceruloplasmin and lipid hydroperoxide (LOOH) levels.
MATERIALS AND METHODS: In a cross-sectional trial, blood samples were collected from patients with HG (n = 25) and healthy pregnant women (n = 25) as control group. Serum TAO activities, -SH levels and LOOH levels and ceruloplasmin levels were measured.
RESULTS: Serum TAO activity was found to be significantly lower (p = 0.003) in patients with HG compared with controls. However, serum -SH levels, LOOH levels and ceruloplasmin levels did not change significantly in patients with HG compared to controls.
CONCLUSION: Presence of oxidative stress in HG patients depends more on reduced antioxidant activities than increased oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24041031     DOI: 10.3109/14767058.2013.842549

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  3 in total

1.  Dynamic thiol-disulfide homeostasis in hyperemesis gravidarum.

Authors:  M Ergin; B D Cendek; S Neselioglu; A F Avsar; O Erel
Journal:  J Perinatol       Date:  2015-07-09       Impact factor: 2.521

2.  The oxidative stress index increases among patients with hyperemesis gravidarum but not in normal pregnancies.

Authors:  Saynur Yilmaz; A Seval Ozgu-Erdinc; Canan Demirtas; Gulfer Ozturk; Salim Erkaya; Dilek Uygur
Journal:  Redox Rep       Date:  2014-10-18       Impact factor: 4.412

3.  Comparison of Serum Ykl-40 and Ischemia Modified Albulmin Levels Between Pregnant Women with Hyperemesis Gravidarum and Normal Pregnant Women.

Authors:  Murat Bulanık; Nevin Sağsöz; Cemile Dayangan Sayan; Mahmut İlkin Yeral; Üçler Kısa
Journal:  Med Arch       Date:  2019-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.